Table 1.
Baseline demographic and clinical characteristics of patients.
| Patient characteristics | GA cohort (N = 120) | Non-GA cohort (N = 60) | P-value |
|---|---|---|---|
| Age (years), mean ± SD | |||
| At baseline | 44.5 ± 10.6 | 40.7 ± 10.21 | 0.025 |
| At MS diagnosis | 35.4 ± 10.92 | 31.4 ± 8.73 | 0.023 |
| Female, n (%) | 76 (63.3) | 45 (76.3)1 | 0.082 |
| MS course n (%) | |||
| RRMS | 112 (93.3) | 52 (86.7) | 0.138 |
| SPMS | 8 (6.7) | 8 (13.3) | |
| Baseline EDSS scores, mean ± SD | 2.0 ± 1.34 | 2.4 ± 1.74 | 0.133 |
| Number of relapses in the year previous to starting the study treatment, mean ± SD | 0.97 ± 0.18 | 0.98 ± 0.13 | 0.521 |
| Baseline EQ-5D index values, mean ± SD | 0.76 ± 0.11 | 0.73 ± 0.14 | 0.133 |
| MS length at baseline (months), mean ± SD | 61.2 ± 74.34 | 67.3 ± 83.64 | 0.626 |
EDSS, Kurtzke's Expanded Disability Status Scale; EQ-5D, EuroQoL 5D; GA, glatiramer acetate; MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SD, standard deviation; SPMS, secondary progressive multiple sclerosis.
1
Missing data, n = 1
2
Missing data, n = 15
3
Missing data, n = 10; 4Missing data, n = 4.